The regenerative medicine category is predicted to generate $39.33 billion in revenue by 2023, with the fastest growth expected in cell therapy.

As another indicator of the category’s rapid growth, the Alliance for Regenerative Medicine, in its progress report for the first half of 2021, noted that there are 1320 industry-sponsored trials of regenerative medicine and advanced therapies ongoing worldwide and an additional 1328 ongoing trials sponsored by non-industry groups, including academic centers and governments.

These trends provided the impetus for Considerations for the Clinical Development of Cell & Gene Therapies, a two-part panel discussion featuring C-suite leaders from advanced therapy companies at the American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting.

In this white paper, we share the exclusive insights from Part 1 of this insightful discussion moderated by Precision’s David Parker.

Read Part 1 now!